Project

Biotechnology netherlands

Supravision

Age-related macular degeneration (AMD) is the foremost cause of vision impairment in the industrialized world, and no effective treatments are available. The number of patients is expected to increase globally, from around 200 million in 2020 to nearly 300 million in 2040. The condition tremendously impacts reading, face recognition, and driving, causing a loss of independence and quality of life. AMD patients are categorized as wet (10-20%) or dry (80-90%). Treatments exist for wet AMD, but they only alleviate symptoms and delay progression. No treatment exists for dry AMD. Ultimately, both groups reach the same end stage: retinal degeneration leading to blindness, typically within 5-10 years of diagnosis. SupraVision B.V. aims to commercialize a regenerative therapy for AMD. We are developing an implant that replaces the damaged tissue and restores visual function. The implant is an advanced therapeutic medical product consisting of a retinal cell layer (RPE) on top of a biodegradable carrier membrane. Within the BiotechBooster level I project, we aim to make SupraVision B.V. investor-ready. Activities include (1) a feasibility study to scale up and work towards GMP compliance, (2) generating a detailed regulatory roadmap according to EMA compliance, and (3) creating a business plan and performing a market analysis.

Project team

Céline Koster, Theodoor Smit, Anna El-Kalaani, Ambre Lemaistre, Steven van Huiden

Project Number

BIOB24055

Year granted

2024

Status

Applicant

Amsterdam University Medical Center

Funding

€ 200.000

Sector/Industry

SDG's

Thematic Cluster

TC3: ATMPs, Biopharmaceuticals & Associated Enabling Technologies

Level

Molecuul

2024

Year granted

Amsterdam University Medical Center

Applicant

€ 200.000

Project funded

Biotech Booster Pilot with Ideation Lab

Bringing biotech innovations from lab to market is no easy task—especially when it comes to early-stage market validation, a step

Biotech Booster Pilot with Ideation Lab

Impact Developers Meeting in Leeuwarden

Impact Developers are a vital part of Biotech Booster’s expertise team. As pioneers in this new role, they work to

Impact Developers Meeting in Leeuwarden

Still millions available for life sciences projects to make an impact through the National Growth Fund

Although the National Growth Fund has been wound down following its third round of funding, several millions are still available

Still millions available for life sciences projects to make an impact through the National Growth Fund

Introducing Lucia Malone

In this series “Meet the people behind Biotech Booster” we introduce you to the passionate people who are involved in

Introducing Lucia Malone

First patient with systemic sclerosis treated with T-Guard

Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, enrolled the first patient in a

First patient with systemic sclerosis treated with T-Guard

Turning Research into Impact: The Role of Universities of Applied Sciences

How do we ensure that research doesn’t just stay on paper, but actually contributes to solving real-world challenges in society,

Turning Research into Impact: The Role of Universities of Applied Sciences
Citaat

Biotech Booster helps us through funding and by providing us with a network to validate where we can make the best impact with our new analysis device.

Biotechnology netherlands

Carlos de Lannoy

Constellate

Citaat

What we look forward to most is leveraging the extraordinary network of Biotech Booster that we need to get foot in the market, get know-how, and understanding the competitive field which is necessary for setting up successful operations.

Biotechnology netherlands

Pim Schaasberg & Martin Pabst

ProteoT

Moleculen

Newsletter

Receive monthly updates about our community!

Subscribe to our newsletter